NASDAQ:ONTX - Onconova Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.69 -0.01 (-0.27 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$3.69
Today's Range$3.60 - $3.81
52-Week Range$1.69 - $20.85
Volume50,247 shs
Average Volume170,212 shs
Market Capitalization$20.92 million
P/E Ratio-0.09
Dividend YieldN/A
Beta2.53
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONTX
CUSIPN/A
Phone267-759-3680

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$790,000.00
Book Value($15.11) per share

Profitability

Net Income$-24,090,000.00
Net Margins-1,610.44%

Miscellaneous

Employees25
Market Cap$20.92 million
Next Earnings Date3/14/2019 (Estimated)
OptionableNot Optionable

Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics shares reverse split before market open on Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics Inc (NASDAQ:ONTX) posted its earnings results on Tuesday, August, 14th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.20) by $0.15. The biopharmaceutical company earned $0.49 million during the quarter, compared to analysts' expectations of $0.52 million. Onconova Therapeutics had a negative return on equity of 965.58% and a negative net margin of 1,610.44%. View Onconova Therapeutics' Earnings History.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Onconova Therapeutics.

What price target have analysts set for ONTX?

2 analysts have issued 12 month price targets for Onconova Therapeutics' shares. Their forecasts range from $16.00 to $25.00. On average, they anticipate Onconova Therapeutics' stock price to reach $20.50 in the next year. This suggests a possible upside of 455.6% from the stock's current price. View Analyst Price Targets for Onconova Therapeutics.

What is the consensus analysts' recommendation for Onconova Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Onconova Therapeutics.

What are Wall Street analysts saying about Onconova Therapeutics stock?

Here are some recent quotes from research analysts about Onconova Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $25 price target. Our clinical NPV model, driven by rigostertib in MDS, allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Onconova Therapeutics, Inc." (2/8/2019)
  • 2. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (1/16/2019)
  • 3. Maxim Group analysts commented, "Onconova reported 2Q18 with a net loss of $4.3M and ended the period with $29.5M in cash, runway into 2H19." (8/14/2018)

Has Onconova Therapeutics been receiving favorable news coverage?

Press coverage about ONTX stock has been trending somewhat positive recently, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Onconova Therapeutics earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.

Who are some of Onconova Therapeutics' key competitors?

What other stocks do shareholders of Onconova Therapeutics own?

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the folowing people:
  • Dr. Ramesh Kumar, Co-Founder, CEO & Director (Age 63)
  • Dr. Steven M. Fruchtman, Pres (Age 68)
  • Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 75)
  • Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 56)
  • Mr. Mark Patrick Guerin, Chief Financial Officer (Age 50)

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (0.23%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, E Premkumar Reddy, Henry S Bienen, Mark Patrick Guerin, Michael B Hoffman and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.

Which major investors are buying Onconova Therapeutics stock?

ONTX stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP. Company insiders that have bought Onconova Therapeutics stock in the last two years include 683 Capital Management, Llc, E Premkumar Reddy, Henry S Bienen, Mark Patrick Guerin and Ramesh Kumar. View Insider Buying and Selling for Onconova Therapeutics.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $3.69.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $20.92 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-24,090,000.00 in net income (profit) each year or ($40.16) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.

What is Onconova Therapeutics' official website?

The official website for Onconova Therapeutics is http://www.onconova.com.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]


MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  400
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel